Population-based e-records to evaluate HPV triage of screen-detected atypical squamous cervical lesions in Catalonia, Spain, 2010-15 by De Sanjose, Silvia et al.
RESEARCH ARTICLE
Population-based e-records to evaluate HPV
triage of screen-detected atypical squamous
cervical lesions in Catalonia, Spain, 2010–15
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Abstract
Equivocal lesions (ASC-US) are common abnormalities in cervical cancer screening
exams. HPV testing helps to stratify the risk of progression to high-grade squamous intrae-
pithelial lesions or more (HSIL+). Population-based medical electronic data can be used to
evaluate screening recommendations. The study uses routine electronic data from primary
health centers to estimate the impact of HPV testing in a 3- and a 5-year risk of HSIL+ after
an ASC-US. The study includes data derived from medical electronic information from
85,775 women who first attended a cervical cancer screening visit at the National Health
System facilities of Catalonia, Spain, during 2010–11 and followed up to 2015. Included
women were aged between 25–65 years old, having at least one follow-up visit, and a cervi-
cal cytology of ASC-US (N = 1,647). Women with a first result of low-grade squamous
intraepithelial lesions (LSIL) (N = 945) or those with negative cytology (N = 83,183) were
included for comparison. Those with a baseline HSIL+ were excluded. Incident HSIL+ was
evaluated by means of Kaplan-Meier curves and multivariate regression models. HPV test
results were available for 63.4% of women with a baseline ASC-US. Among all ASC-US, 70
incident HSIL+ were identified at 5 years. ASC-US HPV positive women had a high risk of
HSIL+ compared to women with negative cytology (adjusted HR = 32.7; 95% CI: 23.6–45.2)
and a similar risk to women with baseline LSIL (HR = 29.3; 95% CI: 22.4–38.2), whereas
ASC-US HPV negative women had no differential risk to that observed in baseline negative
cytology. Women with ASC-US and no HPV test had an average HSIL+ risk (HR = 14.8;
95% CI: 9.7–22.5). Population-based e-medical records derived from primary health care
centers allowed monitoring of screening recommendations, providing robust estimates for
the study outcomes. This analysis confirms that HPV testing improved risk stratification of
ASC-US lesions. The information can be used to improve diagnosis and management of
screen detected lesions.
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Introduction
Equivocal lesions (atypical squamous cells of undetermined significance [ASC-US]) are com-
mon abnormalities detected in population-based cervical cancer screening [1,2]. However, not
all women with a cytology diagnosis of ASC-US have the same risk to develop or harbor high-
grade squamous intraepithelial lesions or more (HSIL+), and triage with oncogenic or so-
called “high risk” human papillomavirus (HPV) types through HPV DNA detection is now
considered essential to determine risk and subsequent management [3–5]. More than half of
ASC-US lesions are estimated to harbor HPV DNA, providing a higher accuracy to detect cer-
vical intraepithelial neoplasia grade 2 or more (CIN2+) lesions as compared to repeated cytol-
ogy [6]. ASC-US HPV positive women have been showed to have a cumulative risk of CIN2+
that goes beyond 10% and above 4% of CIN3+ in long follow-up series [1,7]. ASC-US HPV
positive women therefore need close follow-up until a repeated negative cytology or a negative
HPV test exclude ongoing disease [4,8]. Conversely, ASC-US HPV negative women have a
very low risk of CIN2+ and are recommended to follow a regular screening interval [1,9].
In Spain, a country with historically low rates of invasive cervical cancer, screening has
largely been based on conventional cytology under an opportunistic scenario. Systematic eval-
uation of screening records in the region of Catalonia indicate that abnormal cytology results
account for around 3% of cervical cytologies in any given screening round, of which 96.5% are
ASC-US or LSIL [2]. At present, HPV testing is widespread for ASC-US management [10,11].
This study explores the incidence of HSIL+ among women attending their first cervical cancer
screening exam in a minimal window of 3 years to follow-up.
Material and methods
This study was approved by the Clinical Research Ethics Committee and the Institutional
Review Board of the University Institute for Primary Care Research (IDIAP) Jordi Gol (P15/
106).
In the region of Catalonia, opportunistic cervical cancer screening is offered for free by the
National Health System (NHS) and delivered through the public primary care network. Since
2006, Catalan NHS guidelines established that a 13 high-risk HPV types DNA test (HC2, Qia-
gen, Germantown, MD) was recommended after a diagnosis of ASC-US within 3 months of
the conventional cytology result. Women with an HPV negative test are sent back to a 3-years
regular screening schedule while those with an HPV positive result are referred to immediate
colposcopy [12].
Specific information for the purpose of this analysis was extracted from the NHS electronic
data provided by the Information System of the Primary Health Care facilities (SISAP). The
SISAP holds data from 279 Primary Health Centers and 28 Sexual and Reproductive Health
Clinics. The SISAP stores the NHS primary care clinical data of approximately 75% of the resi-
dent population in Catalonia [13,14]. We requested information on age, place of birth, recruit-
ment health region, date and results of cervical cytology and HPV testing, and ICD-10 codes
for any cervical-related intraepithelial lesion or cancer [15]. Age at first cytology was estimated
as the number of complete years between July 1 in the woman’s year of birth and the date of
the first cytology. Cytology refers to conventional cytology evaluated at the local pathology
departments. The results were reported according to the Bethesda System categories as carci-
noma, HSIL, atypical squamous cells cannot rule out HSIL (ASC-H), LSIL, ASC-US, and nega-
tive for intraepithelial lesion or malignancy [16]. The outcome selected for this analysis was
HSIL+ that included cytology results of HSIL and cervical carcinoma or histology (when avail-
able) diagnosis of CIN2, CIN3 or cervical squamous carcinoma, cervical adenocarcinoma, and
cervical adenosquamous.
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The HPV DNA test result was included in the analysis if it was performed within a window
of 60 days since the first cytology record. A window of 90 days would have resulted in includ-
ing additional 62 women of which 52% remained positive. All women with a baseline diagno-
sis of ASC-H and HSIL+ were excluded from this analysis as these women are referred for
immediate colposcopy and treatment.
Study population
We identified 142,284 women aged 25–65 residing in Catalonia and having a first cervical can-
cer screening visit during 2010–11 at NHS facilities. Women with a baseline diagnosis of
ASC-H or HSIL+ (N = 453) were excluded from this analysis, leaving 141,831 women as the
target population. Of them, 85,775 women (60.5%) were included in the final analysis as they
had at least one additional screening test up to December 2015 when we closed the study win-
dow time. The remaining women (N = 56,056, 39.5%) were considered lost to follow-up as
they did not return within an interval of 3 years or more after the first cytology. These women
were significantly older (44.3 vs. 42.8, p < 0.001), and in particular women aged 60–65 years
were almost twice as likely not to return for a second exam. Lost to follow-up women were
also more likely to be born outside Spain (14.8% vs. 13.2%, p< 0.001), residing outside Barce-
lona (27.1% vs. 23.8%, p< 0.001), and more likely to have a negative screening result at base-
line (98.9% vs. 97.0%, p = < 0.001) (Table 1).
Statistical analysis
Kaplan-Meier curves were used to draw the probability to develop HSIL+ over time. Curves
were stratified by baseline screening results and age group: negative cytology, ASC-US HPV
positive, ASC-US HPV negative, ASC-US with unknown HPV status, and LSIL and two age
groups, < 35 years and 35+. Time to event was measured as person-months from the baseline
cytology until an HSIL+ diagnosis or until the last cytology result, within the study period, for
the remaining cytology results. Log-rank tests and the Renyi test were used to evaluate sub-
group differences between cumulative incidence curves [17,18].
Multivariable logistic regression models with a complementary log-log binomial regression
were used to estimate hazard ratio (HR) of HSIL+ and 95% confidence intervals (CI) [19].
Data analyses were conducted using R (R Foundation for Statistical Computing, Version
3.1.1, Vienna, Austria) and Stata (Stata 138 Statistical Software Release 15, StataCorp LLC, Col-
lege Station, TX).
Results
Table 1 describes the characteristics of the study population at baseline and of those with HSIL
+ at the end of the study period. The average age of the population was 42.8 (± 10.5) years.
Women aged 40–44 years was the largest age group (16.7%) while those aged 60–65 years was
the smallest (7.3%). A clear majority of women were born in Spain (86.8%) and were resident
in the Barcelona catchment area (76.2%). At baseline, 83,183 women (97.0%) had a negative
cytology, 945 (1.1%) LSIL, and 1,647 (1.9%) ASC-US, of which 36.6% did not have a concomi-
tant HPV test associated. Among those with an HPV test, 52% had a negative test. Average fol-
low-up time was 40.6 months (± 12.9). During the study period, 393 women (0.5%) were
diagnosed with HSIL+ that originated in the ASC-US (N = 77), in LSIL (N = 77) and in
women with a negative cytology (N = 246) as baseline categories. Globally, HSIL+ cases were
significantly more likely to be younger (37.5 years) and to be from the Barcelona catchment
area than those with no HSIL+.
HPV triage in ASC-US
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Fig 1 shows Kaplan-Meier probability curves to develop HSIL+ stratified by age group and
baseline screening results. The probability curve of HSIL+ among ASC-US HPV positive was
statistically similar to that of LSIL (p = 0.58 among < 35 years old and p = 0.61 for those> 34
years old). Similarly, ASC-US HPV negative women and women with a negative cytology
result harbored a similar probability of HSIL+ over time p = 0.50 among < 35 years old and
p = 0.29 for those> 34 years old). Conversely, the probability of HSIL+ among ASC-US with
unknown HPV status differed by age : younger women aged less than 35 years old had a simi-
lar detection profile of HSIL+ to that observed for ASC-US HPV positive, whereas older
women aged 35 years or more presented an intermediate pattern between ASC-US HPV posi-
tive and ASC-US HPV negative.
Table 2 describes the incidence rate of HSIL+ and the HR of HSIL+ by baseline screening
results adjusted by age and catchment areas. Follow-up time was slightly shorter for LSIL and
ASC-US HPV positive women (34.5 and 35.3 months) compared to other categories. Women
with an ASC-US HPV negative had a similar HR to women with a negative cytology (HR = 1).
While women with an ASC-US HPV positive or with LSIL both had a similar increased HSIL
+ risk compared to women with a negative cytology (HR = 32.7; 95% CI: 23.6–45.2; HR = 29.3;
95% CI: 22.4–38.2, respectively). Results were similar for both age groups 25–35 years and�
35+ years with the exception of those aged� 35+ years with an ASC-US with unknown HPV
result in which the risk of HSIL was of significantly lower compared to that of HPV positive,
although it remained high (HR = 19.8; 95% CI: 11.6–33.8).
Table 1. Characteristics of the study population attending screening for the first time in 2010–11 by final category at the end of the follow-up period in 2015.
Total Negative for HSIL+ HSIL+ P value
N = 85,775 N = 85,382 (99.5%) N = 393 (0.45%)
Age mean (SD) 42.8 (10.5) 42.8 (10.5) 37.5 (9.1) <0.001
Age group N (%) <0.001
25–29 10,272 (12.0) 10,188 (11.9) 84 (21.4)
30–34 11,547 (13.5) 11,462 (13.4) 85 (21.6)
35–39 13,009 (15.2) 12,939 (15.2) 70 (17.8)
40–44 14,349 (16.7) 14,279 (16.7) 70 (17.8)
45–49 12,356 (14.4) 12,308 (14.4) 48 (12.2)
50–54 9,896 (11.5) 9,883 (11.6) 13 (3.3)
55–59 8,047 (9.4) 8,038 (9.4) 9 (2.3)
60–65 6,299 (7.3) 6,285 (7.4) 14 (3.6)
Place of birth N (%) 0.058
Abroad 11,309 (13.2) 11,244 (13.2) 65 (16.5)
Spain 74,466 (86.8) 74,138 (86.8) 328 (83.5)
Catchment area N (%) 0.004
Non-Barcelona 20,453 (23.8) 20,384 (23.9) 69 (17.6)
Barcelona 65,322 (76.2) 64,998 (76.1) 324 (82.4)
Baseline screening category N (%) <0.001
Negative 83,183 (97.0) 82,937 (97.1) 246 (62.6)
ASC-US & HPV- 543 (0.6) 543 (0.64) 0 (0)
ASC-US & HPV+ 501 (0.6) 455 (0.53) 46 (11.7)
ASC-US no HPV� 603 (0.7) 579 (0.68) 24 (6.1)
LSIL 945 (1.1) 868 (1.02) 77 (19.6)
Time of follow-up (months) 40.6 (12.9) 40.7 (12.9) 32.6 (18.2) <0.001
�HPV test not reported or inexistent within 60 days of the cervical cytology result
https://doi.org/10.1371/journal.pone.0207812.t001
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Table 2 describes the detailed time related probability to HSIL+ by result of first screening
cervical cytology and by age group.
Discussion
Using a large population-based data set, the study confirms the predictive value of HPV triage
in screen-detected ASC-US for HSIL+. This, to our knowledge, is the first report of these char-
acteristics in Spain and adds to the value of molecular approaches to cervical cancer screening.
The data confirm that women with a diagnosis of ASC-US HPV negative had a very low risk of
HSIL+ compared to women with a negative cytology and in line with Demarco et al., support-
ing managing algorithms based on risk estimation [20]. Conversely, ASC-US HPV positive
women had a more than 29-fold increase in risk of HSIL+ comparable to that observed among
women with a cytology result of LSIL. The results are consistent with those from randomized
trials [21] and observational data [22]. The data confirm that ASC-US HPV positive women
have a short time to disease detection as also observed by others [23]. The fact that the risk of
HSIL+ in ASCU-US HPV positive women remained high in the observation period is likely to
be explained in part by delays in referral to colposcopy and getting a final diagnosis rather
than a precursor lesion that has evolved during the observation window. One of the major
Fig 1. Probabilities to develop high-grade squamous intraepithelial lesion or more (HSIL+) during follow-up by age group and baseline screening diagnosis.
ASC-US: atypical squamous cells of undetermined significance; HPV: human papillomavirus; LSIL: low-grade squamous intraepithelial lesion; HSIL+: high-grade
squamous intraepithelial lesion or more.
https://doi.org/10.1371/journal.pone.0207812.g001
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advantages of the risk stratification is that patients should benefit from immediate referral to
colposcopy, avoiding additional delays.
The similarity in risk for HSIL+ of ASC-US HPV positive and LSIL strongly suggests that
management of both entities should be the same as recommended in the European Union
guidelines [4]. The guidelines propose that women with ASC-US or LSIL at triage after an ini-
tial HPV primary test in a screening episode may be followed up by retesting, preferably after
6–12 months, or referred directly to colposcopy. Although risk of progression during a limited
time window may be minimal [24], patient satisfaction is likely to increase by diminishing the
time of the overall process from suspicion to diagnosis and treatment. We could not identify
statistically significant differences between the two age categories before and after 35 years old.
Therefore, the data suggest that for both ASC-US HPV positive and LSIL women, a wait and
see for 24 months remains a reasonable strategy irrespective of age in the absence of a better
triage test that further stratifies risk.
We had evidence of 11 invasive cervical cancers among HSIL+, 2 of them arising in the
baseline category of ASC-US HPV positive result at age 26 and age 37. The time at diagnosis
was 30 and 42 years old, respectively. Most likely, the total number of invasive cervical cancer
cases in our series was underestimated as only those cases recorded by the general practitioner
could be retrieved. This reporting is not compulsory and thus a comprehensive accountability
at the primary health level cannot be guaranteed. Three out of the 11 cervical cancer cases
were diagnosed in the 25–34 age group, of which 2 had as a baseline diagnosis a negative cytol-
ogy and another case had an LSIL. Whether these results justify co-testing with HPV in youn-
ger women is a subject of discussion, and cost-efficiency analysis generally do not support this














Negative 83,183 282,620.8 40.8 (± 12.7) 246 0.087 Reference
ASC-US & HPV negative 543 1,716.4 37.9 (± 15.8) 0 0 ~1
ASC-US & HPV positive 501 1,474.6 35.3 (± 17.5) 46 3.1 32.7 (23.6–45.2)
ASC-US unknown HPV 603 1,790.4 35.6 (± 17.6) 24 1.3 14.8 (9.7–22.5)
LSIL 945 2,720.3 34.5 (± 18.3) 77 2.8 29.3 (22.4–38.2)
Women 25–34 y.o.
Negative 20,729 69,339.6 40.1 (± 14.3) 106 0.15 Reference
ASC-US & HPV negative 144 466.3 38.6 (± 16.6) 0 0 ~1
ASC-US & HPV positive 260 760.7 35.1 (± 18.2) 19 2.5 16.5 (10.0–27.0)
ASC-US unknown HPV 212 636.5 36.0 (± 17.4) 9 1.4 9.4 (4.7–18.6)
LSIL 474 1,396.7 35.3 (± 18.5) 35 2.5 16.5 (11.2–24.3)
Women � 35 y.o.
Negative 62,454 213,281.2 41 (± 12.1) 140 0.07 Reference
ASC-US & HPV negative 399 1,250.1 37.6 (± 15.6) 0 0 ~1
ASC-US & HPV positive 241 713.9 35.5 (± 16.8) 27 3.8 61.5 (40.4–93.5)
ASC-US unknown HPV� 391 1,153.8 35.4 (± 17.7) 15 1.3 19.8 (11.6–33.8)
LSIL 471 1,323.6 33.7 (± 18.1) 42 3.2 49.3 (34.8–70.0)
SD: standard deviation; ASC-US: atypical squamous cells of undetermined significance; HPV: human papillomavirus; LSIL: low-grade squamous intraepithelial lesion;
HSIL+: low-grade squamous intraepithelial lesion or more; CI: confidence interval; HPV test not reported or inexistent within 60 days of the cervical cytology result
aAdjusted for age and recruitment area.
�HPV test not reported or inexistent within 60 days of the cervical cytology result
https://doi.org/10.1371/journal.pone.0207812.t002
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approach as many women would be carriers of acute infections not leading to disease. The aim
of screening remains to have a test with high sensitivity followed by a good triage test. Maybe
even if HPV is common in this age group, co-testing with automated cytology and HPV testing
could provide a better case ascertainment than cytology alone [25,26]. To use HPV testing
alone in younger women may induce too much anxiety of largely spontaneously regressing
infections.
This study is based on routinely collected medical information at the primary health level.
By extracting specific indicators, the data base allowed evaluation of screening practices in the
absence of specific screening registries. The analysis presented informed about adhesion to
general guidelines and recommendations in a routine clinical environment, covering a large
population, both at geographic extent and size, and thus providing real-life estimates. How-
ever, drawbacks include information losses and disparities in data collection and clinical man-
agement over time or among health care providers. In our case, cytological records could not
be comprehensively linked to colposcopy and histological confirmation results. Nevertheless, a
substantial number of HSIL+ had an accompanying medical diagnosis qualifying the severity
of the lesion underneath the cytology result that certified the result.
The consistency of our results with study-based projects indicate that the first step of the
screening purposes, to detect HSIL+, has been clearly accomplished within the ASC-US strata
particularly when HPV testing is done. It would have been desirable to obtain the full differen-
tiation of CIN2 and CIN3+ of these lesions to evaluate potential overdiagnosis and overtreat-
ment of doubtful cancer precursor lesions as CIN2.
The analysis of HSIL+ risk among ASC-US and HPV detection here presented has provided
a strong basis to confirm the value of HPV detection for risk stratification and indicate the
safety for HSIL+ risk of 5-year interval in negative results. In addition, the data presented will
be relevant as baseline information and will allow evaluating future changes in cervical cancer
screening policies. While HPV testing has provided an excellent tool to stratify risk in
ASC-US, the possible introduction of the HPV test as a primary screening tool may result in
larger improvement in risk stratification of participants to screening of cervical cancer. The
possibility of setting up a robust data collection system to evaluate triage recommendations is a
major achievement under the scope of opportunistic screening. We believe that these results
can be of interest to countries that are re-evaluating their cervical cancer screening algorithms
from using conventional cytology and moving toward introducing HPV testing.
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